Why Cytokinetics, Incorporated (CYTK) stock moved
Cytokinetics, Incorporated (CYTK) shares rose 0.1% to $80.27 as of July 20, 2026, a slight gain from the prior close of $80.18. BestStocks flagged the session as a material change for CYTK. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CYTK climbed 0.1% to $80.27
CYTK rose 0.1% in its latest session, moving from $80.18 to $80.27.
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.1% session move. Weighing against that: Cytokinetics, Incorporated (CYTK) moved -2.74% from $82.62 to $80.36 on 2026-07-16; Cytokinetics, Incorporated (CYTK) moved -3.10% from $84.87 to $82.24 on 2026-07-13. Wall Street's consensus price target sits at $109.56, implying +36.5% upside from $80.27. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 17 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $80.27, up $0.09 (+0.11%) from the previous close of $80.18. The session traded on 0.2× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $109.56, 36.5% above the recent $80.27. Over the past 90 days analysts logged 1 upgrade, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
The bullish case
- Wall Street's consensus price target of $109.56 implies +36.5% upside from $80.27.
- The Street's most bullish target is $140.00 (+74.4%).
- 1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-06-29).
- Positive 0.1% session move.
The bearish case
- Cytokinetics, Incorporated (CYTK) moved -2.74% from $82.62 to $80.36 on 2026-07-16.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CYTK
Frequently asked questions about CYTK
Why did Cytokinetics, Incorporated (CYTK) stock move?
CYTK rose 0.1% to $80.27. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CYTK stock rise?
CYTK gained 0.11% ($0.09) versus the prior close of $80.18, last trading at $80.27 on 0.2× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2026-08-06 — about 17 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $109.56, about 36.5% above the current $80.27. Over the past 90 days, analysts recorded 1 upgrade, 10 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CYTK-specific materiality thresholds, triggering an evidence check. It draws on 3 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.